These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 27878441

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B.
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
    Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR.
    J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report].
    Miyazaki Y.
    Nihon Ronen Igakkai Zasshi; 2017 Nov; 54(1):75-80. PubMed ID: 28202889
    [Abstract] [Full Text] [Related]

  • 7. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
    Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH.
    Eur J Neurol; 2018 Mar; 25(3):464-468. PubMed ID: 29115008
    [Abstract] [Full Text] [Related]

  • 8. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L.
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [Abstract] [Full Text] [Related]

  • 9. Tafamidis: a review of its use in familial amyloid polyneuropathy.
    Scott LJ.
    Drugs; 2014 Aug; 74(12):1371-8. PubMed ID: 25022953
    [Abstract] [Full Text] [Related]

  • 10. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN, Deeks ED.
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [Abstract] [Full Text] [Related]

  • 11. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
    Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, French Network for FAP (CORNAMYL).
    Eur J Neurol; 2013 Dec; 20(12):1539-45. PubMed ID: 23834402
    [Abstract] [Full Text] [Related]

  • 12. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR.
    Neurology; 2012 Aug 21; 79(8):785-92. PubMed ID: 22843282
    [Abstract] [Full Text] [Related]

  • 13. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F, Volpe R, Pastorelli F, Bianchi A, Vella A, Rapezzi C, Mascalchi M.
    J Stroke Cerebrovasc Dis; 2018 Sep 21; 27(9):e212-e214. PubMed ID: 29779881
    [Abstract] [Full Text] [Related]

  • 14. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
    Coelho T, Inês M, Conceição I, Soares M, de Carvalho M, Costa J.
    Neurology; 2018 Nov 20; 91(21):e1999-e2009. PubMed ID: 30333157
    [Abstract] [Full Text] [Related]

  • 15. Tafamidis for transthyretin amyloidosis.
    de Lartigue J.
    Drugs Today (Barc); 2012 May 20; 48(5):331-7. PubMed ID: 22645721
    [Abstract] [Full Text] [Related]

  • 16. Motor excitability measurements in early stage familial amyloid polyneuropathy: The influence of tafamidis treatment.
    Casanova I, Caetano A, Díaz A, Conceição I, Brum M, de Carvalho M.
    Neurophysiol Clin; 2020 Jul 20; 50(3):145-153. PubMed ID: 32507631
    [Abstract] [Full Text] [Related]

  • 17. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
    Cárdenas-Soto K, Dominguez XH, Cortes G, Tsai F, Saniger MDM, Guraieb-Chahin P, Torres-Ocatvo B, Gibbons C, Kelly JW, Freeman R, González-Duarte A.
    J Peripher Nerv Syst; 2024 Jun 20; 29(2):221-231. PubMed ID: 38706223
    [Abstract] [Full Text] [Related]

  • 18. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
    Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR.
    J Cardiovasc Transl Res; 2013 Dec 20; 6(6):1011-20. PubMed ID: 24101373
    [Abstract] [Full Text] [Related]

  • 19. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ.
    Orphanet J Rare Dis; 2018 Dec 17; 13(1):225. PubMed ID: 30558645
    [Abstract] [Full Text] [Related]

  • 20. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
    Conceição I, Miranda B, Castro J, de Carvalho M.
    Eur J Neurol; 2018 Nov 17; 25(11):1320-e115. PubMed ID: 29924456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.